Lazertinib Side Effects

Medically reviewed by Drugs.com. Last updated on Feb 10, 2025.

Applies to lazertinib: oral tablets.

Side effects include:

Most common adverse reactions (≥20%) of lazertinib in combination with amivantamab: rash, nail toxicity, infusion-related reaction (amivantamab), musculoskeletal pain, edema, stomatitis, VTE, paresthesia, fatigue, diarrhea, constipation, COVID-19, hemorrhage, dry skin, decreased appetite, pruritus, nausea, ocular toxicity.

Most common Grade 3 or 4 laboratory abnormalities (≥2%) of lazertinib in combination with amivantamab: decreased albumin, decreased sodium, increased ALT, decreased potassium, decreased hemoglobin, increased AST, increased GGT, increased magnesium.

For healthcare professionals

Applies to lazertinib: oral tablet.

General adverse events

All the reported adverse events are those described in patients who received this drug in combination with amivantamab. The most common adverse events (all grades) were rash, nail toxicity, musculoskeletal pain, edema, stomatitis, venous thromboembolism, paresthesia, fatigue, constipation, COVID-19, hemorrhage, dry skin, decreased appetite, pruritus, nausea, and ocular toxicity.^[Ref]

Cardiovascular

• Very common (10% or more): Venous thromboembolism (36%)^[Ref]

Dermatologic

• Very common (10% or more): Rash (86%), nail toxicity (71%), dry skin (24%), pruritus (24%)^[Ref]

Gastrointestinal

• Very common (10% or more): Stomatitis (43%), diarrhea (31%), constipation (29%), nausea (21%), vomiting (12%), abdominal pain (11%), hemorrhoids (10%)^[Ref]

Hematologic

• Very common (10% or more): Decreased albumin (89%), decreased platelet count (52%), decreased hemoglobin (47%), decreased white blood cells (38%), hemorrhage (25%), decreased neutrophils (15%)^[Ref]

Hepatic

• Very common (10% or more): Decreased alanine transaminase (65%), decreased aspartate transaminase (52%)^[Ref]

Musculoskeletal

• Very common (10% or more): Musculoskeletal pain (47%)^[Ref]

Nervous system

• Very common (10% or more): Paresthesia (35%), dizziness (14%), headache (13%)^[Ref]

Ocular

• Very common (10% or more): Ocular toxicity (16%), conjunctivitis (11%)^[Ref]

Psychiatric

• Very common (10% or more): Insomnia (10%)^[Ref]

Renal

• Very common (10% or more): Increased creatinine (26%)

Respiratory

• Very common (10% or more): Cough (19%), dyspnea (14%)
• Common (1% to 10%): Interstitial lung disease or pneumonitis

Metabolic

• Very common (10% or more): Increased alkaline phosphatase (45%), decreased calcium (41%), decreased gamma-glutamyl transferase (39%), decreased sodium (38%), decreased potassium (30%), decreased magnesium (25%), decreased appetite (24%), increased magnesium (12%)^[Ref]

Other

• Very common (10% or more): Edema (43%), fatigue (32%), COVID-19 (26%), pyrexia (12%)^[Ref]

See also:

Further information

Lazertinib side effects can vary depending on the individual. Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Note: Medication side effects may be underreported. If you are experiencing side effects that are not listed, submit a report to the FDA by following this guide.

Medical Disclaimer